Compare Incyte Corporation (INCY) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Annaly Capital Management, Inc. — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Annaly Capital Management, Inc. trades at $18.3 (market cap $13.77B). The key difference: Incyte Corporation is the larger of the two by market cap, and Annaly Capital Management, Inc. pays a 16.42% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Annaly Capital Management, Inc. for 91 Days on average.
| INCY | NLY | |
|---|---|---|
Market Cap | $22.85B | $13.77B |
Volume | 1,927,029 | 21,283,879 |
Sector | Health | Real Estate |
52-Week High | $129.93 | $24.40 |
52-Week Low | $83.80 | $17.93 |
Typical Hold Time | 33 Days | 91 Days |
Enterprise Value | $18.35B | $135.80B |
Dividend Yield | — | 16.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
NLY trades at $18.27, up 1.9% with strong earnings momentum after beating estimates for three consecutive quarters. The stock offers a compelling 16.4% dividend yield with a recent increase to $0.75 per share. Valuation appears attractive with a P/E of 4.41 and P/B of 0.91, though technical indicators show bearish momentum. The company has demonstrated portfolio expansion from $73B in 2023 to $107B in 2026, driving earnings growth.
NLY presents a high-yield opportunity with discounted valuation and consistent earnings beats, but faces interest rate sensitivity and technical headwinds. The 57% analyst buy rating and $22 consensus target suggest 20% upside potential, though investors must weigh the attractive yield against mortgage REIT volatility and recent price weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
